๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 13 Beijing 13 Hangzhou 10 Guangzhou 9 Nanjing 5
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai13 Beijing13 Hangzhou10 Guangzhou9 Nanjing5
All 24 locations
Target enrolment
to

Trials with a site in Beijing

13 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC ( LUXUS07.1 )
NCT07720921Urothelial Carcinoma of the Renal Pelvis and Ureter, Neoadjuvant Therapy
Peking University First Hospital
Phase 2
20
Beijing
2026-08-01
Recruiting
Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer
NCT07458529Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy, Immunotherapy, Probio-M9
Seventh Medical Center of PLA General Hospital
Phase 2
50
Beijing
2026-02-10
Recruiting
Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
NCT07492342Resectable NSCLC, KRAS G12C Mutation, Stage IB-IIIA NSCLC, Neoadjuvant Therapy
Jianxing He
Phase 2
30
Beijing, Guangzhou, Zhejiang
2026-01-29
Not yet open
A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
NCT07086326NSCLC, Neoadjuvant Therapy, Immunotherapy, AK112
Yang Fan, MD
Phase 2
164
Beijing, Changsha, Shanghai, Xiโ€™an, Hangzhou
2025-07-31
By invitation
Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer๏ผˆUPGRADE-TNBC๏ผ‰
NCT06910072Triple-Negative Breast Cancer (TNBC), Neoadjuvant Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2/3
32
Beijing
2025-07-21
Recruiting
Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
NCT07359040Non-Small Cell Lung Cancer, Neoadjuvant Therapy, PD-1 Inhibitors, Immunotherapy
Peking University People's Hospital
Observational
80
Beijing
2025-07-01
Recruiting
FAP-targeted PET/NIR in Lung Malignant Tumors
NCT07498933Non-Small Cell Lung Cancer, PET/CT, Neoadjuvant Therapy
Peking University People's Hospital
Observational
200
Beijing
2025-06-03
Recruiting
To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)
NCT07291921Lung Neoplasms, Neoadjuvant Therapy, Immunotherapy, Minimal Residual Disease
Peking University People's Hospital
Observational
100
Beijing
2025-05-08
Recruiting
Using 4D Urinary Proteomics to Predict and Evaluate Treatment Response in Colorectal Cancer
NCT06904677Colorectal Cancer (CRC), Neoadjuvant Therapy, Proteomics
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
400
Beijing
2025-05-01
Not yet open
Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer
NCT05983094Breast Cancer, Neoadjuvant Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
181
Beijing
2023-09-01
Recruiting
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
NCT06102395Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, Pembrolizumab
Beijing Tongren Hospital
Phase 3
272
Beijing
2023-05-01
Active, closed
Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy
NCT05383716Non Small Cell Lung Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitor
Peking Union Medical College Hospital
Phase 2
80
Beijing
2022-07-01
Recruiting
Multi-points and Full-thickness Biopsy in the Diagnosis of cCR After Neoadjuvant Therapy for Rectal Cancer
NCT04743102Rectal Cancer, Neoadjuvant Therapy, Complete Remission, Metastasis
Beijing Chao Yang Hospital
Not applicable
260
Beijing
2021-01-01
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

8 of the 13 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3 have not yet opened recruitment, 1 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 13 studies
PhaseStudiesRecruitingShare
Phase 26246.2%
Observational4430.8%
Not applicable117.7%
Phase 2/3107.7%
Phase 3117.7%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences31
Peking University People's Hospital33
Beijing Chao Yang Hospital11
Beijing Tongren Hospital11
Jianxing He11
Peking Union Medical College Hospital10
Peking University First Hospital10
Seventh Medical Center of PLA General Hospital11
Yang Fan, MD10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.